-
Product Insights
Turner Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Turner Syndrome - Drugs In Development, 2023’, provides an overview of the Turner Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Turner Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
X-Ray Systems Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
X-Ray Systems Pipeline Market Report Overview X-ray systems use high-energy radiation to diagnose diseases. The X-Ray Systems pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Direct Digital Radiography (DDR) X-ray Systems ·       Flat Panel...
-
Sector Analysis
National Hockey League (NHL) 2023-24 – Analyzing Sponsorship Deals, League and Brand/Partner Breakdown
National Hockey League (NHL) 2023-24 Report Overview The estimated annual sponsorship revenue of the National Hockey League (NHL) is $480.05 million for the 2023-2024 season. The league follows a standard seasonal format, whereby each team completes 82 regular season games, 41 at home and 41 away. The teams are divided into two conferences, the East and West; these are then split into two sub-divisions which make up the main basis of competition for all franchises. The National Hockey League (NHL) 2023-24...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACP-017 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-017 in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-017 in Melanoma Drug Details: Small molecule is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Growth Hormone Deficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Growth Hormone Deficiency report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Growth Hormone Deficiency Drug Details: Ibutamoren...
-
Product Insights
Turner Meadow Solar Station
Turner Meadow Solar Station is a solar PV project located in Maine, United States. The project is owned and being developed by Glenvale Solar LLC. The project is at the permitting stage. Empower your strategies with our Turner Meadow Solar Station report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Product Insights
Turner Solar PV Park
Turner Solar PV Park is a solar PV project located in Virginia, United States. The project is owned and being developed by Cypress Creek Solutions. The project is at the permitting stage. Empower your strategies with our Turner Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Product Insights
Gasna 31P Solar PV Park
Gasna 31P Solar PV Park is a solar PV project located in California, United States. The project is owned by Turner Renewable Energy and was developed by Gestamp Asetym Solar North America, Inc.. The project came online in 2015. Empower your strategies with our Gasna 31P Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PLX-51107 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PLX-51107 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: PLX-51107 was under development...